Sign in

    Gloria Gaddy

    Research Analyst at Private Investor

    Gloria Gaddy is a Research Analyst at Private Investor with a specialization in covering biotechnology firms, notably engaging with PURE BIOSCIENCE. Her recent performance includes participation in earnings calls for PURE BIOSCIENCE, but available data does not offer comprehensive performance metrics such as ranked success rates or returns generated. Gaddy's career timeline, including previous employers and exact joining date at Private Investor, is not publicly disclosed, nor are specific professional credentials such as FINRA registration or securities licenses verifiable at this time. Despite limited published achievements, her role indicates focused expertise in biotech sector analysis.

    Gloria Gaddy's questions to PURE BIOSCIENCE (PURE) leadership

    Gloria Gaddy's questions to PURE BIOSCIENCE (PURE) leadership • Q4 2018

    Question

    Gloria Gaddy, a Private Investor, asked for an update on the business from iGPS's pallet sanitizing program and questioned the reasons for the prolonged testing and lack of adoption by poultry companies since trials began in September 2017.

    Answer

    CEO Hank Lambert responded that the iGPS partnership has not generated significant ongoing revenue due to slower-than-expected customer adoption of their pallet sanitizing program. Regarding the poultry market, Lambert identified the high cost of PURE Control at the required 160 PPM concentration as the primary obstacle. Despite a compelling value proposition over toxic alternatives like PAA, the cost difference has hindered adoption. He stated the company is actively working to optimize the formula's PPM and application flow rate to reduce the overall cost for poultry processors.

    Ask Fintool Equity Research AI